Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...
Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...
Asianet Newsable on MSN
RXRX stock heads for its best day in over a year – what’s driving the rally today?
Sanofi selected its first drug development candidate under its collaboration with Recursion.
Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
When studying programming, you notice something strange.Processes that are extremely complex for humans to think through can ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...
What happens when an AI becomes capable of observing itself, modifying its internal structure, and retraining itself? Using ...
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
The Anthropic CEO's warnings about the dangers posed by AI are raising important questions about the AI lab's growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results